文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺切除术后生化复发前列腺癌挽救性放疗后勃起功能保留:SAKK 09/10 随机 3 期试验五年结果

Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-04-25

SAKK 09/10 随机 3 期试验评估剂量强化挽救性放疗对前列腺切除术后生化复发前列腺癌患者勃起功能的影响,344 例可评估患者接受 64 Gy 或 70 Gy 挽救性放疗。随访 5 年时 101 例(29.4%)患者为 G0-2 级勃起功能障碍,64 Gy 与 70 Gy 组间勃起功能、性活动和性功能均无差异。年龄、放疗技术等因素与长期勃起功能结局相关。

要点

  • 前列腺切除术后 197 例(57.3%)为 G0-2 级勃起功能障碍,147 例(42.7%)为 G3 级。
  • 挽救性放疗后 5 年 101 例(29.4%)患者为 G0-2 级勃起功能障碍。
  • 64 Gy 与 70 Gy 组间勃起功能、性活动和性功能均无差异。

核心结论

  • 前列腺切除术后勃起功能障碍是已知长期副作用,显著影响患者生活质量。
  • 挽救性放疗进一步影响勃起功能障碍,但剂量强化对勃起功能恢复或新发勃起功能障碍患病率无显著影响。
  • 年龄、肿瘤分期、前列腺切除术和放疗技术、神经保留和观察时间与长期勃起功能结局相关。

研究设计与样本

  • 多中心随机试验(2011 年 2 月至 2014 年 4 月),患者接受 64 Gy 或 70 Gy 挽救性放疗。
  • 纳入标准为前列腺切除术后生化失败且随机化时 PSA ≤ 2 ng/ml。
  • 344 例患者可评估,勃起功能障碍为次要终点,采用 CTCAE v4.0 和 EORTC QoL 问卷 C30 与 PR25 在基线和挽救性放疗后 up to 5 年评估。

主要发现

  • 前列腺切除术后 197 例(57.3%)患者为 G0-2 级勃起功能障碍,147 例(42.7%)为 G3 级。
  • 挽救性放疗后 5 年 101 例(29.4%)患者为 G0-2 级勃起功能障碍。
  • 随访期间,基线 G3 级勃起功能障碍患者中 44.2% 显示任何改善,基线 G0-2 级患者中 61.4% 显示恶化。
  • 前列腺切除术与挽救性放疗开始之间较短时间间隔(p = 0.007)和随机化时年龄较大(p = 0.005)是长期更多基线勃起功能障碍和低性活动的显著预测因素。
  • 年龄(p = 0.010)和放疗技术(p = 0.031)对长期 G3 级勃起功能障碍发生和更差性功能有显著影响。

关键数值与推荐

  • 64 Gy 与 70 Gy 组间在随访期间勃起功能、性活动和性功能方面无差异。
  • 基线 G3 级勃起功能障碍患者中 44.2% 显示任何改善。
  • 基线 G0-2 级勃起功能障碍患者中 61.4% 显示恶化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate effects of dose intensified salvage radiotherapy (sRT) on erectile function in biochemically recurrent prostate cancer (PC) after radical prostatectomy (RP). MATERIALS AND METHODS: Eligible patients had evidence of biochemical failure after RP and a PSA at randomization of ≤ 2 ng/ml. Erectile dysfunction (ED) was investigated as secondary endpoint within the multicentre randomized trial (February 2011 to April 2014) in patients receiving either 64 Gy or 70 Gy sRT. ED and quality of life (QoL) were assessed using CTCAE v4.0 and the EORTC QoL questionnaires C30 and PR25 at baseline and up to 5 years after sRT. RESULTS: 344 patients were evaluable. After RP 197 (57.3 %) patients had G0-2 ED while G3 ED was recorded in 147 (42.7 %) patients. Subsequently, sexual activity and functioning was impaired. 5 years after sRT, 101 (29.4 %) patients noted G0-2 ED. During follow-up, 44.2 % of patients with baseline G3 ED showed any improvement and 61.4 % of patients with baseline G0-2 ED showed worsening. Shorter time interval between RP and start of sRT (p = 0.007) and older age at randomization (p = 0.005) were significant predictors to more baseline ED and low sexual activity in the long-term. Age (p = 0.010) and RT technique (p = 0.031) had a significant impact on occurrence of long-term ED grade 3 and worse sexual functioning. During follow-up, no differences were found in erectile function, sexual activity, and sexual functioning between the 64 Gy and 70 Gy arm. CONCLUSION: ED after RP is a known long-term side effect with significant impact on patients' QoL. ED was further affected by sRT, but dose intensification of sRT showed no significant impact on erectile function recovery or prevalence of de novo ED after sRT. Age, tumor stage, prostatectomy and RT-techniques, nerve-sparing and observation time were associated with long-term erectile function outcome.ClinicalTrials.gov. Identifier: NCT01272050.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zwahlen DR, Schröder C, Holer L, et al. Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial. Clin Transl Radiat Oncol. 2024. PMID: 38706726. doi:10.1016/j.ctro.2024.100786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。